Table 3.
Clinical data of the study women at 8 months after treatment
| Group | n | Cytology | HPV | Pathology | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NILM | ASCUS | LSIL | HSIL/ASC‐H | − | 16+ | 18+ | Non 16/18+ | − | CIN1 | CIN2 | CIN3 | ||
| Thermo † | 65 | 65 | 0 | 0 | 0 | 56 | 1 | 1 | 7 | 6 | 3 | 0 | 0 |
| Cryo † | 62 | 55 | 5 | 0 | 2 | 50 | 2 | 0 | 10 | 11 | 1 | 1 | 1 |
| Refer T ‡ | 4 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | ||||
ASC‐H, atypical squamous cells, cannot exclude HSIL; ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasm; Cryo, cryotherapy; HPV, human papillomavirus; HSIL, high‐grade squamous intraepithelial lesion; LSIL, low‐grade squamous intraepithelial lesion; NILM, negative for squamous intraepithelial lesion or malignancy; Thermo, thermocoagulation.
†
A further eight women were lost to follow up at 8 months after treatment (thermocoagulation, n = 3; cryotherapy, n = 5).
‡
Four women randomized to the cryotherapy group who were immediately referred for thermocoagulation due to large lesions uncoverable by the cryoprobe.